Tobacco consumption is a reversible risk factor associated with reduced successful treatment outcomes of anti-tuberculosis therapy  by Chiang, Yi-Chun et al.
International Journal of Infectious Diseases 16 (2012) e130–e135Tobacco consumption is a reversible risk factor associated with reduced successful
treatment outcomes of anti-tuberculosis therapy
Yi-Chun Chiang a,b, You-Meei Lin a,c, Jen-Ai Lee a, Chun-Nin Lee d, Hsiang-Yin Chen a,b,*
a College of Pharmacy, Taipei Medical University, Taipei, Taiwan
bDepartment of Pharmacy, Wan Fang Hospital, Taipei Medical University, 111, Sec. 3, Hsing-Long Rd, Taipei 116, Taiwan
cDepartment of Pharmacy, Shuang Ho Hospital, Taipei Medical University, Taipei County, Taiwan
dDepartment of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei County, Taiwan
A R T I C L E I N F O
Article history:
Received 13 April 2011
Received in revised form 13 September 2011
Accepted 24 October 2011
Corresponding Editor: Sheldon Brown,
New York, USA
Keywords:
Tuberculosis
Smoking
Treatment outcome
Drug therapy
Risk factors
S U M M A R Y
Objective: The aim of this study was to evaluate the reversible factors that could possibly affect outcomes
of anti-tuberculosis (anti-TB) treatment.
Methods: A retrospective observational nested case–control study was performed to evaluate the
association of patient and clinical factors with anti-TB therapy outcomes as deﬁned by the World Health
Organization (WHO).
Results: To examine the impact of a variety of factors on the outcomes of anti-TB treatment, a total of 302
TB patients were included in the study. Univariate analysis revealed that age, gender, concurrent
hypertension, asthma/chronic obstructive pulmonary disease, or liver disease, worsened baseline blood
urea nitrogen or creatinine, ethambutol <800 mg/day, hepatitis or adverse skin reactions during
therapy, smoking history, and current tobacco consumption were signiﬁcant factors in decreasing both
the cure rate and treatment completion rate. However, multivariate regression showed that only age,
current daily tobacco consumption, baseline liver disease, and ethambutol dosage were independent
factors. A high level of tobacco consumption (>20 cigarettes per day) was signiﬁcantly associated with a
decreased odds of cure or treatment completion (odds ratio 0.23, 95% conﬁdence interval 0.05–0.98,
p = 0.047).
Conclusions: As smoking signiﬁcantly inhibits the effectiveness of TB treatment, the integration of
smoking cessation into TB treatment programs is strongly advocated to reduce the dual global burden of
smoking and TB.
Crown Copyright  2011 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
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Tuberculosis (TB), an infectious disease caused by Mycobacteri-
um tuberculosis, is one of the priorities listed in the Millennium
Development Goals.1 The second Global Plan to Stop TB program
(2006–2015) of the World Health Organization (WHO) aims to
halve the global prevalence and death rate of TB by 2015 relative to
1990 levels.2 Gains will come from setting case management
standards and the implementation of modern evidence-based
treatment regimens with directly observed therapy (DOTS).3
However, many variables can affect clinical outcomes and
subsequently challenge the prevalence and morbidity of TB. TB
treatment outcomes may be improved by using effective regimens
with the evaluation of risk factors.* Corresponding author. Tel.: +886 2 29307930 ext. 1157; fax: +886 2 86621163.
E-mail address: shawn@tmu.edu.tw (H.-Y. Chen).
1201-9712/$36.00 – see front matter . Crown Copyright  2011 Published by Elsevier 
doi:10.1016/j.ijid.2011.10.007A number of risk factors have been identiﬁed. Irreversible
factors such as age,4–7 sex,7–10 HIV infection,5,7,11 and socioeco-
nomic status (e.g., low income12) cannot be altered. Among the
known reversible risk factors, smoking affects the rate of positive
sputum cultures and is involved with immunological responses
that can be modiﬁed by aggressive strategies. Although previous
research has revealed the association between tobacco smoking
and higher morbidity, mortality, and worse surrogate endpoints
of TB, the ultimate impact of smoking on deﬁnite outcomes has
not been explicitly studied. Three meta-analyses have concluded
that cigarette smoking is related to an increased incidence of
latent TB infection, disease, and mortality.13–15 Passive exposure
to tobacco smoke has been reported to increase the likelihood of
diseases and prevalence.13,16 Smoking has been shown to be
associated with worse clinical surrogate endpoints, such as an
increased number of pulmonary cavity lesions,17 positive smear
readings,17 an increased likelihood of hospitalization,17 and
delayed sputum smear conversion.18 However, the summativeLtd on behalf of International Society for Infectious Diseases. All rights reserved.
Figure 1. Study ﬂow chart.
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detailed investigation.
The aim of this nested case–control study was to identify the
risk factors associated with the ﬁnal treatment outcomes of anti-TB
therapy and to determine their signiﬁcance vis-a`-vis the popula-
tion of Taiwan. By using the WHO deﬁnitions for TB outcomes, the
study provides new evidence to strengthen current practices of TB
treatment.
2. Methods
This retrospective observational nested case–control study was
approved by the Institutional Review Board of Wan Fang Hospital,
Taipei Medical University, a 750-bed tertiary medical center. The
hospital is the ofﬁcial center for TB treatment in the south of Taipei
City and initiates treatment for more than 200 newly diagnosed
patients annually, of whom more than 60 are usually referred from
other institutions.
The diagnosis of TB relies on the clinical signs and symptoms of
patients, as well as the results of acid-fast smear (at least two
positive readings among three specimens obtained on separate
days), chest radiography, histology, and culture. Wan Fang
Hospital follows the recommendations of the Infectious Diseases
Society of America,19 and treats newly diagnosed TB patients with
a once-daily ﬁxed-dose combined formulation.
Prescribed anti-TB agents include isoniazid 320 mg, rifampin
480 mg, ethambutol 800 mg, and pyrazinamide 1000 mg for an
initial 2 months, and isoniazid 300 mg, rifampin 450 mg for the
following 4 months for patients weighing less than 50 kg. Patients
weighing more than 50 kg are prescribed with the following adjusted
dose: isoniazid 400 mg, rifampin 600 mg, ethambutol 800 mg, and
pyrazinamide 1250 mg for the initial 2 months, and isoniazid
300 mg, rifampin 600 mg for the following 4 months. In addition,
renal dosage adjustment for ethambutol was also performed.
However, Taiwan’s Center for Disease Control only started imple-
menting the DOTS strategies in April of 2006 and therefore this was
not applicable to the patients included in this study.
2.1. Study population
Newly diagnosed TB patients who started their TB treatment
between July 2001 and June 2003 with four standard ﬁrst-line anti-
TB drugs were selected using the hospital’s computerized medicalmanagement system. Patients who had been diagnosed with
cancer, multiple drug-resistant TB, or HIV infection were then
excluded. For the purpose of identifying the occurrence of adverse
drug reactions and treatment outcomes, those who never returned
for follow-up visits, received anti-TB drugs for less than 7 days, or
who transferred out to other health facilities were also excluded
(Figure 1).
2.2. Data collection
Patient data were collected and reviewed from both electronic
records and medical charts. Laboratory data including albumin,
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
total bilirubin, conjugated bilirubin, and serum alkaline phosphate
(ALP) were obtained from the computerized laboratory reporting
system.
The index date (day 1) was deﬁned as the day when a speciﬁc
patient received his/her anti-TB medication for the ﬁrst time at the
hospital. Laboratory data, medication proﬁles, and the occurrence
of adverse events were collected every other day for the ﬁrst week,
then every week until the second month, and ﬁnally every month
until the sixth month. After 6 months, the subjects’ treatment
outcomes were collected either for a further 6 months or until their
therapeutic outcomes were satisﬁed.
An ‘ever-smoker’ was deﬁned as a person who had a history of
smoking at any time-point before the index date or during the
course of therapy. A ‘never-smoker’ was deﬁned as a person who
had not smoked at any time-point before the index date or during
treatment. Patients who stopped smoking in response to being
diagnosed with TB were classiﬁed as ever-smokers. Tobacco
consumption was recorded in units of cigarettes per day. If tobacco
consumption was recorded as a range, the upper limit was used to
avoid underestimation. The smoking status of patients whose
smoking histories were not in the medical records (n = 28) was
assessed through telephone interviews conducted by a trained
pharmacist who was unaware of the treatment outcomes.
2.3. Outcomes of interest
The outcome variables of interest were deﬁned as positive
composite outcomes, including treatment completion conﬁrmed
by a physician’s diagnosis and microbiological cures according to
WHO recommendations.20 The other three categories of outcome
Table 1
Treatment outcomes of the study subjects
Records Deﬁnition No. of patients (%)
Cure Patient who was sputum smear-negative in the last month of treatment and on at least one previous occasion 6 (2.0)
Treatment completed Patient who completed treatment but who did not meet the criteria for classiﬁcation as a cure or a failure 186 (61.6)
Treatment failure Patient who was sputum smear-positive at 5 months or later during treatment 5 (1.7)
Died Patient who died for any reason during the course of treatment 19 (6.3)
Default Patient whose treatment was interrupted for two consecutive months or more 86 (28.5)
Transfer out Patient who was transferred to another recording and reporting unit and for whom the treatment outcome
was not known
Excluded
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classiﬁed as negative treatment outcomes.20 A more detailed
deﬁnition of the outcome components is given in Table 1.
The occurrence of an adverse event was deﬁned as an unwanted
response diagnosed and documented by a physician during anti-TB
therapy, according to widely accepted clinical practice guidelines for
TB treatment21 and the Common Terminology Criteria for Adverse
Events (CTCAE).22 Liver function tests and serum uric acid levels
were used to aid the assessment of drug-related hepatitis and
hyperuricemia. The causality of all adverse events was evaluated by
the Naranjo score,23 and hepatotoxicity was determined by the
Roussel Uclaf Causality Assessment Method (RUCAM) score.24,25
2.4. Statistical analysis
To determine possible factors affecting treatment outcomes,
the Chi-square test and Fisher’s exact test were used to analyze
binary variables. For ordinal variables, a Chi-square test using
Cochran–Mantel–Haenszel statistics was performed. For numeri-
cal variables, the normality of samples was examined using the
Shapiro–Wilk test. Normally distributed continuous variables
were analyzed with an independent t-test, while other continuous
variables were analyzed by way of the Wilcoxon rank-sum test.
The analysis was performed with SAS version 9.1.3 software (SAS
Inc., Cary, NC, USA). A two-tailed p-value of <0.05 was considered
to be statistically signiﬁcant.
Variables included in the initial multivariate regression model
were based on both biological relevance and statistical consider-
ations. The study factor of interest, current levels of tobacco
consumption, was forced into the model after adjustment for age. All
of the other signiﬁcant variables in the univariate tests were further
analyzed using multivariate binary logistic regression. Diabetes
mellitus (DM) was also added to the list of candidates for model
selection due to its biological relevance.26,27 The best-ﬁt model was
determined through automatic stepwise model selection using a
maximum likelihood ratio estimation, with a signiﬁcance level of
0.05 to enter and 0.10 to stay. The Hosmer and Lemeshow method
was applied to examine the goodness-of-ﬁt by using the Akaike
Information Criterion (AIC) as an adjunctive parameter.
3. Results
3.1. Patient characteristics
A total of 333 TB patients who had been treated with a ﬁrst-line
anti-TB regimen were recruited, and 302 patients were included in
the ﬁnal analysis (Figure 1). The patient numbers and corresponding
percentages according to the six different treatment outcomes are
summarized in Table 1. Positive treatment outcomes were observed
in 192 patients (63.6%) over an average duration of 285.2  91.5 days.
3.2. Univariate analysis
Twenty-ﬁve demographic characteristics and other clinical risk
factors were selected for the univariate analysis to determine anassociation with treatment outcomes. Reduced positive treatment
outcomes were observed to be signiﬁcantly associated with 12
factors (Table 2). The ever-smokers had more negative treatment
outcomes than the never-smokers (60% vs. 43.2%, p = 0.005). In
addition, cigarette smoking patients who had a higher current
tobacco consumption were less likely to achieve positive outcomes
(Table 2).
This signiﬁcant association between smoking status and anti-
TB treatment outcome was further conﬁrmed by a series of
subgroup analyses. Smoking history (never smoked, used to
smoke, or current smoker) was found to be a consistently
signiﬁcant risk factor in the drinker subgroup, in the non-DM
subgroup, in the low body mass index (BMI) subgroup (BMI
<18.5 kg/m2), and in the pulmonary TB group (data not presented).
Also, the signiﬁcant association between current tobacco con-
sumption (categorized as no current consumption, 1–20, or >20
cigarettes per day) and outcomes was reproducible in the alcohol
drinker subgroup and in the non-DM subgroup (data not
presented).
3.3. Multivariate analysis
All 12 risk factors that reached statistical signiﬁcance in the
univariate analysis (Table 2) and the factor of co-morbid DM,
interaction term of smoking history/alcoholism, and current tobacco
consumption/alcoholism, were further evaluated using the multi-
variate binary logistic regression model. Current tobacco consump-
tion was forced to enter the model after adjustment for age. The best
model, i.e., that with the smallest AIC value, consisted of four risk
factors: age, current tobacco consumption, baseline liver disease,
and low dose of ethambutol. The p-value of the Hosmer and
Lemeshow goodness-of-ﬁt was 0.379, indicating a good match
between the predicted and observed probabilities in the ﬁnal model.
In this ﬁnal model, high tobacco consumption (>20 cigarettes
per day) was signiﬁcantly associated with a decreased odds of
achieving a positive treatment outcome (odds ratio (OR) 0.23, 95%
conﬁdence interval (CI) 0.05–0.98, p = 0.047), and even moderate
smokers (1–20 cigarettes per day) registered borderline insigniﬁ-
cance (OR 0.61, 95% CI 0.35–1.05, p = 0.073) compared to those
who did not consume tobacco. The decrease in point estimates by
increased tobacco consumption implies a dose–response associa-
tion. The model forced the adjusted patients’ age into baseline. The
odds ratios of patients aged 45–64 and >65 years were 0.46 (95% CI
0.24–0.86) and 0.53 (95% CI 0.29–0.96), respectively, when
compared to those aged under 45 years. Baseline liver disease
was another signiﬁcant risk factor determined by the model,
although this was considered irreversible (OR 0.33, 95% CI 0.12–
0.88, p = 0.026). In addition, a low dose of ethambutol was also
signiﬁcantly associated with a decreased odds of a positive
treatment outcome (OR 0.25, 95% CI 0.09–0.72, p = 0.010).
4. Discussion
Potential risk factors associated with reducing the number of
successful outcomes of anti-TB therapy were evaluated by
Table 2
Univariate analysis of factors evaluated for a possible association with treatment outcomea
Negative outcome (n = 110) Positive outcome (n = 192) p-Value
Age (years), mean  SD 57.8  19.7 51.5  21.3 0.011b
<45 years 29 (26.4) 82 (42.7)
45–64 years 36 (32.7) 46 (24.0)
>65 years 45 (40.9) 64 (33.3)
Gender, male/female 84/26 124/68 0.033b
BMI (kg/m2), mean  SD 19.9  3.1 20.5  3.3 0.384
Concurrent disease
Hypertension 24 (21.8) 20 (10.4) 0.007b
Diabetes mellitus 24 (21.8) 31 (16.1) 0.219
Cardiovascular diseases 19 (17.3) 23 (12.0) 0.201
COPD or asthma 20 (18.2) 19 (9.9) 0.039b
Liver diseases 11 (10) 8 (4.2) 0.045b
Renal diseases 6 (5.5) 7 (3.6) 0.558
Smoking history 0.014b
Never smoked 44 (40) 109 (56.8)
Smoked, but quitted 22 (20) 25 (13.0)
Current smoker 44 (40) 58 (30.2)
Current tobacco consumption 0.026b
No current consumption 66 (61.1) 134 (71.7)
120 cigarettes per day 36 (33.3) 50 (26.7)
>20 cigarettes per day 6 (5.6) 3 (1.6)
Drinking history 36 (32.7) 52 (27.1) 0.299
Baseline laboratory data
AST (mg/dl), mean  SD 26.0  24.7 21.2  21.1 0.076
ALT (mg/dl), mean  SD 25.9  28.3 24.4  29.6 0.729
BUN (mg/dl), mean  SD 17.2  9.1 14.2  7.5 0.008b
SCr (mg/dl), mean  SD 1.38  1.27 1.25  1.43 0.038b
Anti-TB medication dose
Rifampin <600 mg/day 37 (33.6) 55 (28.6) 0.365
Isoniazid <400 mg/day 43 (39.1) 59 (30.7) 0.139
Pyrazinamide <1250 mg/day 40 (36.4) 56 (29.2) 0.196
Ethambutol <800 mg/day 11 (10) 6 (3.1) 0.013b
Any adverse reaction during therapy 52 (47.3) 95 (49.5) 0.712
Elevated LFT 15 (13.6) 22 (11.5) 0.579
Hepatitis 18 (16.4) 14 (7.3) 0.014b
Skin reaction 19 (17.3) 53 (27.6) 0.043b
Hyperuricemia 8 (7.3) 19 (9.9) 0.442
Visual disturbance 10 (9.1) 20 (10.4) 0.711
BMI, body mass index; COPD, chronic obstructive pulmonary disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; SCr, serum
creatinine; TB, tuberculosis; LFT, liver function test; SD, standard deviation.
a Values are number of patients (%), unless otherwise speciﬁed.
b Statistically signiﬁcant, p-value of <0.05.
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tobacco consumption, advanced age, baseline liver disease, and
lower doses of ethambutol were independent risk factors
associated with reduced treatment completion or cure. However,
current daily tobacco consumption was considered to be the only
reversible risk factor. Furthermore, the association was reproduc-
ible when a subgroup analysis was performed on patients who
consumed alcohol, had a low BMI (BMI <18.5 kg/m2), or were
without DM.
Our data suggest a strong association between current tobacco
consumption and ﬁnal treatment outcome. Included in the
possible underlying mechanisms attributable to this association
are that cigarette smoking may: (1) cause a deﬁciency in
respiratory function; (2) affect the immune response; and (3)
interact with the metabolism of anti-TB agents. Cigarette smoking
may also alter the metabolic clearance rate of anti-TB agents by
inducing the activities of cytochrome P450 (CYP) 1A1, CYP1A2,
CYP2E1, and uridine 50-diphosphate (UDP)-glucuronosyltrans-
ferases, thus leading to reduced treatment effectiveness.28–30 A
fourth possible mechanism may be the direct enhancing effect
tobacco components have on the growth kinetics of mycobacteria
in general and M. tuberculosis in particular. More than 4000
molecules have been found in tobacco,31,32 and some of them,
including nicotinic acid, nicotinamide, and a and b nicotinamide
adenine dinucleotide, have been reported as having this effect.33,34This study demonstrated that continuing to smoke during therapy
may signiﬁcantly restrain the effectiveness of TB treatment.
An integrated approach to smoking cessation in TB patients
should be taken to help resolve the dual epidemics of TB and
tobacco use. Regular ofﬁce visits under DOTS supervision are
required for patients on a TB program, and these could provide
teachable opportunities for smoking cessation35 at a limited
operational cost. Physicians and nurses on TB service teams could
have additional smoking cessation training, and DOTS providers
could further support daily behavioral and cognitive therapy to
eliminate the psychological dependence of patients. Helping TB
patients to quit smoking would have the additional beneﬁt of
reducing the chance of transmitting the infection through
secondhand smoke. The beneﬁts, cost-effectiveness, and feasibility
of this approach strongly suggest that smoking cessation be
included into regular TB treatment programs.
Baseline liver disease, a low ethambutol dose, and anti-TB
agent-induced hepatitis carry signiﬁcant weight in determining
the outcome of TB treatment. An underlying liver disorder could
decrease the activities of hepatic enzymes metabolizing anti-TB
agents,36 shown to be a risk factor capable of altering outcomes. A
lower and reasonable dose adjustment of ethambutol adminis-
tered to patients with decreased renal function inevitably
contributed to reducing the number of successful outcomes.
Hepatitis and skin reactions induced by anti-TB agents were also
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echoes previous ﬁndings.4,5,37
Certain limitations of this study should be declared. The
inﬂuence of HIV status on treatment outcomes was not deter-
mined. In comparison to previous studies,5,7,11 AIDS was not
common in Taiwan during the study period (6.9 per 105
individuals).38,39 For this reason it was decided that HIV status
would not constitute a good predictor for this study and therefore
HIV patients were excluded. Furthermore, this study did not
evaluate the association with socioeconomic status, as has been
done in previous publications.40,41 Treatment and medication for
TB are provided free of charge in Taiwan and are fully supported by
the national public health project42 and the national health
insurance system. Finally, DOTS had not yet been implemented
during the study period,43 thus the positive treatment outcome
rate at the end of the ﬁrst year remained relatively low. It should be
noted that these considerations might limit the extrapolation of
the study results.
In conclusion, this study provides direct evidence that cigarette
smoking is a reversible risk factor in reducing the number of
successful outcomes of TB treatment in a dose-dependent manner.
Patients who smoke should have the dosage of their medication
appropriately adjusted, and it would be best to incorporate
smoking cessation into their therapeutic plan. In fact, integrating
smoking cessation into TB control programs should be prioritized
when drawing up national and global guidelines, as this would
help to reduce the dual burden of smoking and TB on society.
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